do you think thats why? i would assume its more around market size/VC location/drug pricing flexibility
-
-
-
I think it’s all of the factors you noted plus speed, a potentially lower safety and efficacy bar, and more accelerated review pathways
- Još 1 odgovor
Novi razgovor -
-
-
"In a study of review times for new therapeutic agents ... the median time from filing to approval by the FDA was 304 days, whereas median time to approval for the EMA and Health Canada were modestly longer at 371 days and 364 days, respectively."
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.